8-K: Bruker to Acquire NanoString Business for $392.6 Million in Asset Deal

Bruker Corporation has agreed to acquire substantially all assets of NanoString Technologies for approximately $392.6 million in cash, expanding its spatial biology portfolio.

Summary

• Bruker Corporation will acquire NanoString Technologies' assets, including the nCounter, GeoMx, CosMx, and AtoMx product lines, for $392.6 million in cash.
• The acquisition was approved through a court-supervised Chapter 11 sale process.
• NanoString generated approximately $168 million in revenue in 2023.
• The deal is expected to close in the second quarter of 2024, pending customary closing conditions.
• Bruker anticipates the acquisition will initially dilute non-GAAP EPS by $0.15 to $0.20 for the remainder of 2024.
• By 2026, Bruker expects the NanoString business to be near break-even with resumed revenue growth and margin improvements.
• Bruker expects its combined Spatial Biology business to achieve double-digit organic revenue growth with increasing non-GAAP EPS accretion by 2027 and beyond.

Sentiment

Score: 6

Explanation: The document presents a strategic acquisition with long-term growth potential, but the near-term financial impact is negative due to dilution and uncertainties. The sentiment is cautiously optimistic.

Positives

• The acquisition will add gene expression profiling and spatial transcriptomics solutions to Bruker's portfolio.
• NanoString's innovative platforms are complementary to Bruker's CellScape spatial proteomics platform.
• Bruker expects high-margin consumables pull-through from the acquired business.
• Bruker has a track record of successfully integrating acquisitions and improving their profitable growth performance.
• The deal is expected to be accretive to non-GAAP EPS by 2027.

Negatives

• The acquisition is expected to be dilutive to non-GAAP EPS by $0.15 to $0.20 for the remainder of 2024.
• NanoString's financial performance cannot be reliably estimated due to the Chapter 11 reorganization and other factors.
• There are uncertainties related to various US and European IP and antitrust litigation proceedings against a competitor.

Risks

• The closing conditions for the transaction may not be satisfied.
• The asset purchase agreement could be terminated.
• The transaction may not be completed in the expected timeframe or at all.
• Bruker may not be able to successfully integrate NanoString and achieve expected synergies.
• Management's attention may be diverted from Bruker's ongoing business operations.
• There is a risk of stockholder litigation and other legal proceedings related to the transaction.
• Announcements related to the transaction could adversely affect Bruker's stock price.
• The transaction could negatively impact NanoString's ability to retain key personnel and maintain business relationships.
• Bruker's financial results may not be consistent with current guidance.

Future Outlook

Bruker expects the NanoString business to rebound and be near break-even by 2026, with the combined Spatial Biology business achieving double-digit organic revenue growth and increasing non-GAAP EPS accretion by 2027 and beyond.

Management Comments

• Dr. Mark R. Munch, President of the Bruker NANO Group, stated that the acquisition will add gene expression profiling and spatial transcriptomics solutions to Bruker's spatial biology portfolio.
• Frank H. Laukien, Bruker's President & CEO, regards Spatial Biology as a key pillar of their strategic focus on the post-genomic era.

Industry Context

This acquisition reflects a growing trend in the life sciences industry towards spatial biology and multiomics solutions. Bruker is positioning itself to be a leader in this space by acquiring a company with established products and a strong customer base.

Comparison to Industry Standards

• The acquisition of NanoString by Bruker is similar to other strategic acquisitions in the life sciences tools sector, where companies seek to expand their product portfolios and market reach.
• Comparable companies in the spatial biology space include 10x Genomics and Akoya Biosciences, which have also seen significant investment and growth.
• The $392.6 million purchase price reflects the value of NanoString's technology and market position, but the financial performance is currently impacted by the Chapter 11 process and ongoing litigation.
• Bruker's expectation of achieving double-digit organic revenue growth by 2027 is in line with the growth potential of the spatial biology market, which is expected to expand rapidly in the coming years.

Legal Proceedings

• The transaction was approved under a court-supervised Chapter 11 sale process.
• There are ongoing US and European IP and antitrust litigation proceedings against a competitor.

Stakeholder Impact

• Shareholders of Bruker may experience short-term dilution of earnings.
• Employees of NanoString will likely transition to Bruker.
• Customers of NanoString will have access to Bruker's broader product portfolio.
• Suppliers of NanoString will become suppliers to Bruker.

Next Steps

• The transaction is expected to close in the second quarter of 2024, subject to customary closing conditions.
• Bruker will integrate the NanoString business into its Spatial Biology business.
• Bruker will work to improve the financial performance of the acquired business and achieve synergies.

Key Dates

Keywords

Bruker, NanoString, acquisition, spatial biology, gene expression, transcriptomics, nCounter, GeoMx, CosMx, AtoMx, Chapter 11, asset deal